Exelixis Inc (EXEL) Overview
- 4 Apr 2026: Period ending 3 Jul 2026; Estimate (m); Actual 0.82; Beat / miss (m).
- 3 Jan 2026: Period ending 3 Apr 2026; Estimate (m); Actual 0.79; Beat / miss (m).
- 5 Jul 2025: Period ending 3 Oct 2025; Estimate (m); Actual 0.69; Beat / miss (m).
- 5 Apr 2025: Period ending 4 Jul 2025; Estimate (m); Actual 0.65; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $69.57
- Previous close
- $58.65
- Change
- $10.92
- Change (%)
- 18.62%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- EXEL
- +33.81%
- S&P 500
- (m)
1 year
- EXEL
- +44.56%
- S&P 500
- (m)
3 years
- EXEL
- +168.42%
- S&P 500
- (m)
5 years
- EXEL
- +184.29%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
3 Jul 2026 ○ Estimate (m) ● Actual 0.82
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 4 Apr 2026 | 3 Jul 2026 | (m) | 0.82 | (m) | (m) |
| 3 Jan 2026 | 3 Apr 2026 | (m) | 0.79 | (m) | (m) |
| 5 Jul 2025 | 3 Oct 2025 | (m) | 0.69 | (m) | (m) |
| 5 Apr 2025 | 4 Jul 2025 | (m) | 0.65 | (m) | (m) |
| 4 Jan 2025 | 4 Apr 2025 | (m) | 0.55 | (m) | (m) |
2 Jan 2026 ○ Estimate (m) ● Actual 2.78
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 4 Jan 2025 | 2 Jan 2026 | (m) | 2.78 | (m) | (m) |
| 30 Dec 2023 | 3 Jan 2025 | (m) | 1.76 | (m) | (m) |
| 31 Dec 2022 | 29 Dec 2023 | (m) | 0.65 | (m) | (m) |
| 1 Jan 2022 | 30 Dec 2022 | (m) | 0.56 | (m) | (m) |
| 2 Jan 2021 | 31 Dec 2021 | (m) | 0.72 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
3 Jul 2026 ■ Revenue 628.69M ■ Earnings 212.05M — Profit margin 33.73%
2 Jan 2026 ■ Revenue 2.32B ■ Earnings 0.78B — Profit margin 33.73%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $69.57 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning EXEL
View more →(m)
Statistics
View more →Retained observations as of 2026-11-13; financial period ending 3 Jul 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $860.65M
- Profit margin
- 35.33%
- Return on assets · 12 month
- 33.28%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 1.08K
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 2.17M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- 0.86%*
- Total return · month
- 7.71%*
- Total return · quarter
- 8.05%*
- Total return · half year
- 41.22%*
- Total return · year to date
- 33.81%*
- Total return · 1 year
- 44.56%*
- Total return · 3 years
- 168.42%*
- Total return · 5 years
- 184.29%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- $2.44B
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
Exelixis Inc Overview
View more →(m)
(m)
- SEC CIK
- 939767
- Industry (SIC)
- 2836 Biological Products, (No Diagnostic Substances)
- Country of operation
- United States
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, California, 94502, United States
- Fiscal year end
- 0101
- Phone
- 6508377000
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |